Roche, Actelion To Develop S1P1 Receptor Agonist For Autoimmune Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche will pay Actelion $75 mil. up-front for co-development and co-marketing rights to the clinical program, now in Phase I.
You may also be interested in...
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.
Actelion Acquires CoTherix For $420 mil.
Swiss firm projects that sales of its newly acquired product Ventavis could add roughly $100 mil. in 2007 revenue.